Biophytis S.A. (ALBPS.PA)
EUR 0.33
(0.92%)
EUR 0.33
(0.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -14.33 Million EUR | 38.41% |
| 2022 | -23.27 Million EUR | 13.21% |
| 2021 | -26.81 Million EUR | -92.33% |
| 2020 | -13.94 Million EUR | 11.1% |
| 2019 | -15.68 Million EUR | -13.14% |
| 2018 | -13.86 Million EUR | -39.9% |
| 2017 | -9.9 Million EUR | -24.75% |
| 2016 | -7.94 Million EUR | -156.29% |
| 2015 | -3.09 Million EUR | -359.78% |
| 2014 | -673.97 Thousand EUR | -35.25% |
| 2013 | -498.32 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.19 Million EUR | 0.0% |
| 2024 Q1 | -2.19 Million EUR | 43.78% |
| 2023 Q2 | -3.26 Million EUR | 0.0% |
| 2023 Q3 | -3.9 Million EUR | -19.7% |
| 2023 FY | -15.89 Million EUR | 31.7% |
| 2023 Q4 | -3.9 Million EUR | 0.0% |
| 2023 Q1 | -3.26 Million EUR | 42.52% |
| 2022 Q2 | -14.53 Million EUR | -143.93% |
| 2022 Q1 | -5.96 Million EUR | 67.71% |
| 2022 FY | -23.27 Million EUR | 13.21% |
| 2022 Q3 | -5.67 Million EUR | 60.96% |
| 2022 Q4 | -5.67 Million EUR | 0.0% |
| 2021 Q4 | -18.45 Million EUR | -126.46% |
| 2021 FY | -26.81 Million EUR | -92.33% |
| 2021 Q1 | -5.25 Million EUR | 34.8% |
| 2021 Q2 | -12.69 Million EUR | -141.45% |
| 2021 Q3 | -8.15 Million EUR | 35.78% |
| 2020 Q4 | -8.06 Million EUR | -138.98% |
| 2020 Q1 | -3.59 Million EUR | 49.85% |
| 2020 Q3 | -3.37 Million EUR | 63.42% |
| 2020 Q2 | -9.22 Million EUR | -156.34% |
| 2020 FY | -13.94 Million EUR | 11.1% |
| 2019 Q1 | -3.5 Million EUR | 14.46% |
| 2019 FY | -15.68 Million EUR | -13.14% |
| 2019 Q4 | -7.17 Million EUR | -136.57% |
| 2019 Q3 | -3.03 Million EUR | 50.43% |
| 2019 Q2 | -6.11 Million EUR | -74.77% |
| 2018 Q3 | -4.09 Million EUR | -46.33% |
| 2018 Q2 | -2.79 Million EUR | 2.98% |
| 2018 Q1 | -2.88 Million EUR | -0.26% |
| 2018 FY | -13.86 Million EUR | -39.9% |
| 2018 Q4 | -4.09 Million EUR | 0.0% |
| 2017 Q2 | -2.07 Million EUR | 0.0% |
| 2017 Q3 | -2.87 Million EUR | -38.23% |
| 2017 Q4 | -2.87 Million EUR | 0.0% |
| 2017 FY | -9.9 Million EUR | -24.75% |
| 2017 Q1 | -2.07 Million EUR | 1.68% |
| 2016 Q4 | -2.11 Million EUR | 0.0% |
| 2016 Q3 | -2.11 Million EUR | -13.99% |
| 2016 Q1 | -1.85 Million EUR | -7.94% |
| 2016 FY | -7.94 Million EUR | -156.29% |
| 2016 Q2 | -1.85 Million EUR | 0.0% |
| 2015 Q1 | -802.5 Thousand EUR | -343.04% |
| 2015 Q2 | -802.5 Thousand EUR | 0.0% |
| 2015 Q4 | -1.71 Million EUR | 0.0% |
| 2015 FY | -3.09 Million EUR | -359.78% |
| 2015 Q3 | -1.71 Million EUR | -114.21% |
| 2014 Q4 | -181.13 Thousand EUR | 0.0% |
| 2014 Q2 | -155.85 Thousand EUR | 0.0% |
| 2014 Q1 | -155.85 Thousand EUR | 0.0% |
| 2014 FY | -673.97 Thousand EUR | -35.25% |
| 2014 Q3 | -181.13 Thousand EUR | -16.22% |
| 2013 FY | -498.32 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -320.076% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 88.747% |
| Adocia SA | -17.62 Million EUR | 18.664% |
| Aelis Farma SA | -6.46 Million EUR | -121.839% |
| Advicenne S.A. | -6.45 Million EUR | -121.976% |
| genOway Société anonyme | 2.06 Million EUR | 793.993% |
| IntegraGen SA | -183.77 Thousand EUR | -7699.423% |
| Medesis Pharma S.A. | -4.22 Million EUR | -238.894% |
| Neovacs S.A. | -6.9 Million EUR | -107.498% |
| NFL Biosciences SA | -4.43 Million EUR | -223.513% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -1741.727% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -356.865% |
| Sensorion SA | -22.31 Million EUR | 35.757% |
| Theranexus Société Anonyme | -7.64 Million EUR | -87.514% |
| TME Pharma N.V. | -5.62 Million EUR | -154.854% |
| Valbiotis SA | -7.16 Million EUR | -100.182% |
| TheraVet SA | -2.17 Million EUR | -558.955% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 29.352% |
| argenx SE | -417.15 Million EUR | 96.564% |
| BioSenic S.A. | -7.04 Million EUR | -103.594% |
| Celyad Oncology SA | -8.45 Million EUR | -69.481% |
| DBV Technologies S.A. | -85.24 Million EUR | 83.186% |
| Galapagos NV | -88.26 Million EUR | 83.761% |
| Genfit S.A. | -26.58 Million EUR | 46.076% |
| GeNeuro SA | -14.35 Million EUR | 0.169% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 10.38% |
| Innate Pharma S.A. | -12.66 Million EUR | -13.134% |
| Inventiva S.A. | -102.7 Million EUR | 86.045% |
| MaaT Pharma SA | -19.94 Million EUR | 28.13% |
| MedinCell S.A. | -20.97 Million EUR | 31.673% |
| Nanobiotix S.A. | -26.77 Million EUR | 46.477% |
| Onward Medical N.V. | -35.46 Million EUR | 59.583% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -215.067% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 37.645% |
| Oxurion NV | -12.11 Million EUR | -18.357% |
| Pharming Group N.V. | -4.87 Million EUR | -193.736% |
| Poxel S.A. | -28.76 Million EUR | 50.17% |
| GenSight Biologics S.A. | -29.69 Million EUR | 51.734% |
| Transgene SA | -30.01 Million EUR | 52.242% |
| Financière de Tubize SA | -2.14 Million EUR | -568.525% |
| UCB SA | 604 Million EUR | 102.373% |
| Valneva SE | -82.08 Million EUR | 82.539% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 50.296% |